Warm Autoimmune Hemolytic Anemia

Research output: Contribution to journalReview articlepeer-review

Abstract

Warm autoimmune hemolytic anemia (AIHA) is defined as the destruction of circulating red blood cells (RBCs) in the setting of anti-RBC autoantibodies that optimally react at 37°C. The pathophysiology of disease involves phagocytosis of autoantibody-coated RBCs in the spleen and complement-mediated hemolysis. Thus far, treatment is aimed at decreasing autoantibody production with immunosuppression or reducing phagocytosis of affected cells in the spleen. The role of complement inhibitors in warm AIHA has not been explored. This article addresses the diagnosis, etiology, and treatment of warm AIHA and highlights the role of complement in disease pathology.

Original languageEnglish (US)
Pages (from-to)445-453
Number of pages9
JournalHematology/Oncology Clinics of North America
Volume29
Issue number3
DOIs
StatePublished - Jun 1 2015

Keywords

  • Autoimmune hemolytic anemia
  • Complement
  • Direct antiglobulin test
  • Spherocyte

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Warm Autoimmune Hemolytic Anemia'. Together they form a unique fingerprint.

Cite this